Bromocriptine 2.5 mg. 30 tablets

COMPOSITION
Active substance: Bromocriptine mesylate 2,87 mg, equiv. of Bromocriptine 2,5 mg in a tabletka.Pomoshtni substances: lactose monohydrate, inositol, wheat starch, colloidal silicon dioxide, tartaric acid, magnesium stearate, carboxymethyl cellulose sodium salt.
 
 
PHARMACEUTICAL FORM AND CONTENTS
Tablets of 2,5 mg, 30 pieces per package
 
 
ACTION
Bromocriptine inhibits increased secretion of prolactin. Does not affect other pituitary hormones, except in patients with acromegaly, in which the use of the formulation reduces the elevated GH. These actions are due to stimulation of the dopamine receptors. Bromocriptine restore normal ovulation and menstrual cycle in women with secondary absence of menstruation. The preparation and pathological influence milky secretion as it significantly reduces or completely disappears during therapy. Through its dopaminergic action improves parkinsonian manifestations.
About 30% of the dose is absorbed in the digestive system. The preparation is 90-96% bound to plasma proteins. The main route of excretion of the drug is via the bile, only 2.5-5% by the kidneys in urine.
 
 
INDICATIONS
Irregular menstruation, infertility in women, premenstrual symptoms, hyperprolactinemia in men, prolactinoma, acromegaly, suppression of lactation, benign breast disease, Parkinson's disease.
 
 
CONTRAINDICATIONS
Severe cardiac disease, uncontrolled hypertension, various forms of endogenous psychoses, toxemia of pregnancy, hypersensitivity to ergot alkaloids and to any component of the preparation.
 
 
PRECAUTIONS
Particular attention is necessary when taking high doses of bromocriptine in patients with underlying disorders of the psyche, severe cardiovascular disease, asbestosis, ulcers or bleeding from the gastrointestinal tract.
With prolonged use is necessary systematic gynecological control patsientkite.Da be used with caution in women after childbirth, especially in the presence of risk factors (hypertension, smoking, obesity, peripheral arteriopathy).
This product contains lactose and starch. Is unsuitable for people with lactase deficiency, galactosemia or glucose / galactose malabsorption. May constitute a danger to patsieniti with celiac disease (gluten enteropathy).
 
 
Use in pregnancy and lactation.
If pregnancy occurs during bromocriptine therapy should be discontinued immediately in patients who wish to preserve the fruit except where there is a medical indication for continued therapy.
 
 
Impact on alertness, the ability to drive and use machines.
Avoid operating a motor vehicle or operating machinery when taking bromocriptine causes lower blood pressure.
 
 
DRUG INTERACTIONS AND OTHER
Bromocriptine should be used with caution simultaneously with drugs that lower blood pressure. Avoid concomitant administration of diuretics, phenothiazine means ergot alkaloids, macrolides, alpha-adrenergic, dopamine antagonists and alcohol.
 
 
ADMINISTRATION AND DOSAGE
The preparation should always be taken at mealtimes.
Dysfunctions associated mainly with hyperprolactinemia: In galactorrhea, amenorrhea, irregular menstruation and infertility, treatment begins with 1,25 mg 2 times a day. The dose is increased over 3-7 days with 1,25 mg to obtain the desired effect. T
erapevtichnata dose is usually 5-7,5 mg daily and range from 2,5-15 mg daily. In puerperal breast swelling and early mastitis - single 2,5 mg, if necessary, the dose may be repeated after 6-12 hours. Hypogonadism 5-10 mg daily. In prolaktinsekretirashti adenomas - at 1,25 mg 2-3 times daily. The dose is gradually increased until the dose that provides optimal level of prolactin plazmata.Akromegaliya: Starts with 1,25-2,5 mg daily and increased to 10-20 mg daily for 1-2 weeks, according to individual need and tolerability of the patient.
Parkinson's disease: Treatment starts with 2,5 mg daily during the two weeks increases with the log 2,5 mg up to a dose of 15-20 mg daily. In some patients required significantly higher dose - 40-50 mg daily. The maximum daily dose should not exceed 100 mg. Combining bromocriptine with other antiparkinson agents enhances the specific effects and makes it possible to reduce the dose.
 
 
OVERDOSE
Observed were nausea, vomiting, dizziness, fall in blood pressure with loss of consciousness, sweating, dizziness and hallucinations. Upon acceptance of higher doses than prescribed, the patient should promptly consult your doctor.
 
 
SIDE EFFECTS
At the beginning of treatment are possible headache, dizziness, fatigue, nausea, vomiting, which do not necessitate interruption of treatment. In rare cases there is a decrease or increase in blood pressure, which is why its necessary to control values. Very rarely encountered Liver disorders, anemia, kidney failure. Observed some skin reactions such as rashes, itching and sensitivity to sunlight. Upon treatment with high doses of bromocriptine were also observed drowsiness, and constipation; in rare cases - disorientation, hallucinations, and dry mouth. All these side effects are dose-dependent and usually amenable to control by reducing it.
Tolerance to bromocriptine may be reduced by alcohol.
 
STORAGE
Dry, dark place at a temperature below 25 ° C. Keep out of reach of children!
 
SHELF LIFE
Two (2) years
The preparation should not be used after the expiry date stated on the package!